Drug details

Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)

type of Antidiabetics, SGLT2 Inhibitors

Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets) is a combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

The drug is often used to treat Type 2 diabetes .

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • nausea,
  • itching,
  • vomiting,
  • lightheadedness,
  • confusion,
  • tiredness,
  • stomach pain,
  • dizziness,
  • weakness,
  • trouble swallowing,
  • little or no urination,
  • feeling cold,
  • unusual drowsiness,
  • pain or burning when you urinate,
  • feeling unwell,
  • severe pain in your upper stomach spreading to your back,
  • blood in your urine,
  • blisters,
  • rapid weight gain
  • unusual muscle pain,
  • feeling very thirsty,
  • irregular heart rate,
  • swelling in your legs or feet, and
  • breakdown of the outer layer of skin,
  • severe or ongoing pain in your joints,
  • flaking or peeling skin,
  • pain in the pelvis or back,
The following drugs are related to Trijardy XR, either as a replacement or used together:
  • Precose (acarbose)
  • Kazano (alogliptin and metformin hcl tablets)
  • Oseni (alogliptin and pioglitazone tablets)
  • Nesina (alogliptin tablets)
  • Invokamet XR (canagliflozin and metformin hydrochloride)
  • Invokamet (canagliflozin and metformin hydrochloride tablets)
  • Xigduo XR (dapagliflozin and metformin hcl extended-release tablets)
  • Synjardy XR Extended-release Tablets (empagliflozin and metformin hydrochloride extended-release)
  • Synjardy (empagliflozin and metformin hydrochloride tablets)
  • Fiasp (insulin aspart injection for subcutaneous or intravenous use)
  • Glumetza (metformin hcl)
  • Glyset (miglitol)
  • NovoLog (insulin aspart [rdna origin] inj)
  • NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin))
  • Tresiba (insulin degludec injection)
  • Levemir (insulin detemir)
  • Lantus (insulin glargine [rdna origin] injection)
  • Toujeo (insulin glargine injection for subcutaneous use)
  • Janumet (sitagliptin metformin hcl)
  • Janumet XR (sitagliptin and metformin hcl)
  • Kombiglyze XR (saxagliptin and metformin hcl extended-release)
  • NovoLog Mix 50/50 (50% insulin aspart protamine suspension and 50% insulin aspart injection)
  • Ozempic (semaglutide injection)
  • Prandimet (repaglinide and metformin hcl tablets)